Steven A Haney

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi RNAi and high-content screening in target identification and validation
    Steven A Haney
    Wyeth Research, Section of Applied Genomics, Department of Biological Technologies, Cambridge, MA 02140, USA
    IDrugs 8:997-1001. 2005
  2. ncbi Increasing the robustness and validity of RNAi screens
    Steven A Haney
    Department of Biological Technologies, Wyeth Research, 35 Cambridge Park Drive, Cambridge, MA 02140, USA
    Pharmacogenomics 8:1037-49. 2007
  3. ncbi Anticancer drug development incorporating high-content screening and RNAi: synergistic approaches to improve target identification and validation
    Steven A Haney
    Wyeth Research, Department of Biological Technologies, 87 Cambridge Park Drive, Cambridge, MA 02140, USA
    Expert Opin Drug Discov 1:19-29. 2006
  4. ncbi Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized
    Yizheng Li
    Section of Bioinformatics, Department of Biological Technologies, Wyeth Research, 87 Cambridge Park Drive, Cambridge, MA 02140, USA
    Mol Cancer 6:7. 2007
  5. ncbi Impact of image segmentation on high-content screening data quality for SK-BR-3 cells
    Andrew A Hill
    Department of Biological Technologies, Wyeth Research, 35 CambridgePark Drive, Cambridge, MA 02140, USA
    BMC Bioinformatics 8:340. 2007
  6. ncbi High-content screening moves to the front of the line
    Steven A Haney
    Department of Biological Technologies, Wyeth Research, 87 Cambridge Park Drive, Cambridge, MA 02140, USA
    Drug Discov Today 11:889-94. 2006
  7. ncbi Increased retention of functional fusions to toxic genes in new two-hybrid libraries of the E. coli strain MG1655 and B. subtilis strain 168 genomes, prepared without passaging through E. coli
    Steven A Haney
    Department of Infectious Disease, Wyeth Research, 401 N, Middletown Rd, Pearl River, NY 10965, USA
    BMC Genomics 4:36. 2003
  8. ncbi Expanding the repertoire of RNA interference screens for developing new anticancer drug targets
    Steven A Haney
    Wyeth Research, Department of Biological Technologies, 35 Cambridge Park Drive, Cambridge, MA 02140, USA
    Expert Opin Ther Targets 11:1429-41. 2007
  9. ncbi Single cell cytometry of protein function in RNAi treated cells and in native populations
    Peter LaPan
    Department of Biological Technologies, Oncology Research, Wyeth Research, 87 Cambridge Park Drive, Cambridge, MA 02140, USA
    BMC Cell Biol 9:43. 2008
  10. ncbi Genomics in anti-infective drug discovery--getting to endgame
    Steven A Haney
    Wyeth-Ayerst Research, 401 N. Middletown Road, Pearl River, NY 10965, USA
    Curr Pharm Des 8:1099-118. 2002

Detail Information

Publications11

  1. ncbi RNAi and high-content screening in target identification and validation
    Steven A Haney
    Wyeth Research, Section of Applied Genomics, Department of Biological Technologies, Cambridge, MA 02140, USA
    IDrugs 8:997-1001. 2005
    ..However, combining RNAi and HCS provides significant and unique advantages to a target validation program...
  2. ncbi Increasing the robustness and validity of RNAi screens
    Steven A Haney
    Department of Biological Technologies, Wyeth Research, 35 Cambridge Park Drive, Cambridge, MA 02140, USA
    Pharmacogenomics 8:1037-49. 2007
    ..This review will discuss how these approaches can improve RNAi screening data at the community level and for an individual researcher trying to manage an RNAi screen...
  3. ncbi Anticancer drug development incorporating high-content screening and RNAi: synergistic approaches to improve target identification and validation
    Steven A Haney
    Wyeth Research, Department of Biological Technologies, 87 Cambridge Park Drive, Cambridge, MA 02140, USA
    Expert Opin Drug Discov 1:19-29. 2006
    ..This review describes RNAi and HCS technologies as they apply to drug target validation, and discusses efforts to integrate them. Particular focus is applied to aspects of HCS that mitigate some of the challenges inherent to RNAi...
  4. ncbi Transcriptional changes associated with breast cancer occur as normal human mammary epithelial cells overcome senescence barriers and become immortalized
    Yizheng Li
    Section of Bioinformatics, Department of Biological Technologies, Wyeth Research, 87 Cambridge Park Drive, Cambridge, MA 02140, USA
    Mol Cancer 6:7. 2007
    ..HMEC that have overcome the second senescence barrier are immortalized...
  5. ncbi Impact of image segmentation on high-content screening data quality for SK-BR-3 cells
    Andrew A Hill
    Department of Biological Technologies, Wyeth Research, 35 CambridgePark Drive, Cambridge, MA 02140, USA
    BMC Bioinformatics 8:340. 2007
    ..We asked if segmentation errors were common for a clinically relevant cell line, if such errors had measurable effects on the data, and if HCS data could be improved by automated identification of well-segmented cells...
  6. ncbi High-content screening moves to the front of the line
    Steven A Haney
    Department of Biological Technologies, Wyeth Research, 87 Cambridge Park Drive, Cambridge, MA 02140, USA
    Drug Discov Today 11:889-94. 2006
    ..The use of HCS in target validation is expanding the work that can be done at this stage, especially the range of targets that can be characterized, and putting it into a more biological context...
  7. ncbi Increased retention of functional fusions to toxic genes in new two-hybrid libraries of the E. coli strain MG1655 and B. subtilis strain 168 genomes, prepared without passaging through E. coli
    Steven A Haney
    Department of Infectious Disease, Wyeth Research, 401 N, Middletown Rd, Pearl River, NY 10965, USA
    BMC Genomics 4:36. 2003
    ..coli or yeast gene products in these systems has been shown to be growth inhibitory, and therefore these clones are underrepresented (or completely lost) in the amplified library...
  8. ncbi Expanding the repertoire of RNA interference screens for developing new anticancer drug targets
    Steven A Haney
    Wyeth Research, Department of Biological Technologies, 35 Cambridge Park Drive, Cambridge, MA 02140, USA
    Expert Opin Ther Targets 11:1429-41. 2007
    ..RNAi screening can enable critical evaluations of both the roles of these concepts in tumor development and provide starting points for new therapeutic programs targeting emerging areas of cancer cell biology...
  9. ncbi Single cell cytometry of protein function in RNAi treated cells and in native populations
    Peter LaPan
    Department of Biological Technologies, Oncology Research, Wyeth Research, 87 Cambridge Park Drive, Cambridge, MA 02140, USA
    BMC Cell Biol 9:43. 2008
    ..Such approaches are important for immune cells analyzed by flow cytometry, but have not been broadly available for adherent cells that are critical to the study of solid-tumor cancers and other disease models...
  10. ncbi Genomics in anti-infective drug discovery--getting to endgame
    Steven A Haney
    Wyeth-Ayerst Research, 401 N. Middletown Road, Pearl River, NY 10965, USA
    Curr Pharm Des 8:1099-118. 2002
    ....
  11. ncbi Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction
    Lee D Jennings
    Wyeth Research, Department of Medicinal Chemistry, 401 N Middletown Road, Pearl River, NY 10965, USA
    Bioorg Med Chem 12:5115-31. 2004
    ..Compounds were demonstrated to bind to the FtsZ binding domain of ZipA by HSQC NMR and to inhibit cell division in a cell elongation assay...